Home » Newsletters » BioWorld Science

BioWorld Science

June 28, 2022

View Archived Issues

ON-203, a second-generation anti-oxMIF antibody with improved efficacy

RAC1 variants found to cause a novel developmental syndrome

LETM1 causes mitochondrial osmotic dysregulation tied to pathology

MagicMed Industries discloses new 5-HT2A receptor agonists

Suzhou Vincentage Pharma patents GLP-1 receptor agonists

Targeting of CD46 allows PET imaging of mesothelioma with [89Zr]DFO-YS5

Chengdu Easton Biopharmaceuticals discloses BET inhibitors

Chinese researchers identify new JAK1 inhibitors

IMPACT Therapeutics synthesizes new NUAK inhibitors

RBM22 inversely correlates with prostate cancer aggressiveness

EAN 2022: At several scales, connective landscape provides lens for neurology

New pH-responsive albumin-binding ligands show targeted tumor uptake in vivo

Use of [89Zr]Prot-FH for neutrophil imaging during fungal infection

Ainos reports preclinical data on low-dose oral interferon-alpha Veldona against COVID-19

Hillstream partners with Sapien to study synergy between HSB-1216 and immune checkpoint inhibitors

NCI grant supports Penn's development of intraoperative imaging technology for NSCLC

Kuria licenses rights to SCOHIA's SCO-116 for ocular and dermatologic diseases

Astellas and Sutro partner to discover and develop novel immunostimulatory antibody-drug conjugates

Ideaya selects Pol Theta Helicase development candidate

Confo awarded grant to support GPCR drug discovery

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...